Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 18/20 | 1.00 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4129844 | 0.89 | FBP1 (1.00) | FBP1TARBP2ALDH1A1CYP1A2 | |
| SCHEMBL4121755 | 0.87 | FBP1 (1.00) | FBP1TARBP2ALDH1A1CYP1A2 | |
| SCHEMBL4134495 | 0.85 | FBP1 (1.00) | FBP1ALDH1A1CYP1A2 | |
| SCHEMBL18974157 | 0.83 | FBP1 (0.71) | FBP1TARBP2ALDH1A1CYP1A2 | |
| SCHEMBL4129692 | 0.82 | FBP1 (1.00) | FBP1TARBP2ALDH1A1CYP1A2 | |
| SCHEMBL4131813 | 0.82 | FBP1 (1.00) | FBP1ALDH1A1CYP1A2 | |
| SCHEMBL3539631 | 0.73 | FBP1 (0.56) | FBP1TARBP2 | |
| SCHEMBL4135529 | 0.71 | FBP1 (0.80) | FBP1ALDH1A1CYP1A2 | |
| SCHEMBL26984766 | 0.70 | FBP1 (0.58) | FBP1TARBP2ALDH1A1CYP1A2 | |
| SCHEMBL26984507 | 0.69 | FBP1 (0.52) | FBP1TARBP2ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | JIANG TAO | 2009-07-30 | — | — | US | disclosed |
| US-20080015195-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | METABASIS THERAPEUTICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7312219-B2 | Heteroaromatic inhibitors of fructose 1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070232571-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-6965033-B2 | Bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1143955-B1 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS INC (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1552850-A2 | A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes | Metabasis Therapeutics, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050004077-A1 | Novel bisamidate phosphonate prodrugs | JIANG TAO (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040167178-A1 | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes | ERION MARK D (US) | 2004-08-26 | — | — | US | disclosed |
| US-20040058892-A1 | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase | DANG QUN (US) | 2004-03-25 | — | — | US | disclosed |
| EP-1112275-B9 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS INC (US) | 2004-03-10 | — | — | EP | disclosed |
| EP-1112275-B1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS INC (US) | 2003-07-30 | — | — | EP | disclosed |
| US-6489476-B1 | FRUCTOSE-1,6-BISPHOSPHATASE ENZYME INHIBITORS ARE USEFUL IN THE TREATMENT OF DIABETES AND OTHER CONDITIONS ASSOCIATED WITH ELEVATED BLOOD GLUCOSE OR EXCESS GLYCOGEN STORAGE. | METABASIS THERAPEUTICS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. | 2002-11-21 | — | — | US | disclosed |
| EP-1143955-A3 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1143955-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1112275-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | Metabasis Therapeutics, Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000038666-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000014095-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058892-A1 | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase | FBP1, G6PC1, HK1 | FBP1 1/4885TARBP2 4037/4885ALDH1A1 739/4885 |
| US-20080015195-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | FBP1, ALDOA, G6PC1 | FBP1 1/4885TARBP2 4043/4885ALDH1A1 640/4885 |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, G6PC1 | FBP1 1/4885TARBP2 3603/4885ALDH1A1 852/4885 |
| US-20050004077-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, PFKFB2 | FBP1 1/4885TARBP2 3359/4885ALDH1A1 1609/4885 |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | FBP1, PFKFB1, PFKFB2 | FBP1 1/4885TARBP2 3359/4885ALDH1A1 1609/4885 |
| US-20040167178-A1 | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes | FBP1, G6PC1, IRS1 | FBP1 1/4885TARBP2 3023/4885ALDH1A1 3879/4885 |
| US-20070232571-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | FBP1, ALDOA, G6PC1 | FBP1 1/4885TARBP2 4043/4885ALDH1A1 640/4885 |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | FBP1, G6PC1, IRS1 | FBP1 1/4885TARBP2 3023/4885ALDH1A1 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.